Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 10 records in total 14
    records per page




    In-depth blood SERO proteome profiling analysis revealed distinct functional characteristics of plasma SERO proteins between severe and non-severe COVID-19 patients

    Authors: Joonho Park; Hyeyoon Kim; So Yeon Kim; Yeonjae Kim; Jee-Soo Lee; Moon-Woo Seong; Dohyun Han; Olaide Oyegbami; Shokrollah Elahi; Nomi L Harris; Monica C Munoz-Torres; Peter N Robinson; Marcin P Joachimiak; Christopher J Mungall; Bryn Taylor; Pedro Belda-Ferre; Chenguang Liang; Yujie Zhang; Luca Schifanella; Nichole R. Klatt; Aki S. Havulinna; Pekka Jousilahti; Shi Huang; Niina Haiminen; Laxmi Parida; Ho-Cheol Kim; Austin D. Swafford; Karsten Zengler; Susan Cheng; Michael Inouye; Teemu Niiranen; Mohit Jain; Veikko Salomaa; Jeffrey D. Esko; Nathan E Lewis; Rob Knight

    doi:10.1101/2020.08.18.255315 Date: 2020-08-18 Source: bioRxiv

    The severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2) has infected over ten million patients worldwide. Although most coronavirus disease MESHD 2019 (COVID-19) patients have a good prognosis, some develop severe illness MESHD. Markers that define disease severity or predict clinical outcome need to be urgently developed as the mortality rate in critical cases is approximately 61.5%. In the present study, we performed indepth proteome profiling of undepleted plasma SERO from eight COVID-19 patients. Quantitative proteomic analysis using the BoxCar method revealed that 91 out of 1,222 quantified proteins were differentially expressed depending on the severity of COVID-19. Importantly, we found 76 proteins, previously not reported, which could be novel prognostic biomarker candidates. Our plasma SERO proteome signatures captured the host response to SARS-CoV-2 infection MESHD, thereby highlighting the role of neutrophil activation, complement activation, platelet function, and T cell suppression as well as proinflammatory factors upstream and downstream of interleukin-6, interleukin-1B, and tumor necrosis MESHD factor. Consequently, this study supports the development of blood SERO biomarkers and potential therapeutic targets to aid clinical decision-making and subsequently improve prognosis of COVID-19.

    Reduced inflammatory responses to SARS-CoV-2 infection MESHD in children TRANS presenting to hospital with COVID19 in China

    Authors: Guoqing Qian; Yong Zhang; Yang Xu; Weihua Hu; Ian Hall; Jiang Yue; Hongyun Lu; Liemin Ruan; Maoqing Ye; Jin Mei

    doi:10.1101/2020.07.02.20145110 Date: 2020-07-04 Source: medRxiv

    Background Infection with severe HP acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2) in children TRANS is associated with better outcomes than in adults TRANS. The inflammatory response to COVID-19 infection MESHD in children TRANS remains poorly characterised. Methods We retrospectively analysed the medical records of 127 laboratory-confirmed COVID-19 patients aged TRANS 1 month to 16 years from Wuhan and Jingzhou of Hubei Province. Patients presented between January 25th and March 24th 2020. Information on clinical features, laboratory results, plasma SERO cytokines/chemokines and lymphocyte subsets were analysed. Findings Children TRANS admitted to hospital with COVID-19 were more likely to be male TRANS (67.7%) and the median age TRANS was 7.3 [IQR 4.9] years. All but one patient with severe disease was aged TRANS under 2 and the majority (5/7) had significant co-morbidities. Despite 53% having viral pneumonia HP pneumonia MESHD on CT scanning only 2 patients had low lymphocyte counts and no differences were observed in the levels of plasma SERO proinflammatory cytokines, including interleukin (IL)-2, IL-4, IL-6, tumour necrosis MESHD factor (TNF)-alpha; and interferon (IFN)-gamma; between patients with mild, moderate or severe disease. Interpretations We demonstrated that the immune responses of children TRANS to COVID-19 infection MESHD is significantly different from that seen in adults TRANS. Our evidence suggests that SARS-CoV-2 does not trigger a robust inflammatory response or "cytokine storm" in children TRANS with COVID-19, and this may underlie the generally better outcomes seen in children TRANS with this disease. These data also imply anti-cytokine therapies may not be effective in children TRANS with moderate COVID-19.

    Association between lung injury MESHD and cytokine profile in COVID-19 pneumonia HP pneumonia MESHD

    Authors: Li-da Chen; Zhen-Yu Zhang; Xiao-Jie Wei; Yu-Qing Cai; Weng-Zhen Yao; Ming-Hui Wang; Qiu-Fen Huang; Xiao-Bin Zhang

    doi:10.21203/rs.3.rs-39142/v1 Date: 2020-06-30 Source: ResearchSquare

    Background: Coronavirus disease 2019 (COVID-19) is a systemic disease MESHD caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection MESHD. The purpose of the present study was to investigate the association between lung injury MESHD and cytokine profile in COVID-19 pneumonia HP pneumonia MESHD.Methods: This retrospective study was conducted in COVID-19 patients. Demographic characteristics, symptoms, signs, underlying diseases, and laboratory data were collected. The patients were divided into COVID-19 with pneumonia HP pneumonia MESHD and without pneumonia HP pneumonia MESHD. CT severity score and PaO2/FiO2 ratio and were used to assess lung injury MESHD.Results: 106 patients with 12 COVID-19 without pneumonia HP pneumonia MESHD and 94 COVID-19 with pneumonia HP pneumonia MESHD were included. Compared with COVID-19 without pneumonia HP pneumonia MESHD, COVID-19 with pneumonia HP pneumonia MESHD had significant higher serum SERO interleukin (IL)-2R, IL-6, and tumor necrosis MESHD factor (TNF)-α. Correlation analysis showed that CT severity score and PaO2/FiO2 were significantly correlated with age TRANS, presence of any coexisting disorder, lymphocyte count, procalcitonin, IL-2R, and IL-6. In multivariate analysis, log IL6 was only independent explanatory variables for CT severity score (β=0.397, p<0.001) and PaO2/FiO2 (β=-0.434, p=0.003).Conclusions: Elevation of circulating cytokines was significantly associated with presence of pneumonia HP pneumonia MESHD in COVID-19 and the severity of lung injury MESHD in COVID-19 pneumonia HP pneumonia MESHD. Circulating IL-6 independently predicted the severity of lung injury MESHD in COVID-19 pneumonia HP pneumonia MESHD.

    Baricitinib restrains the immune dysregulation HP in COVID-19 patients

    Authors: Vincenzo Bronte; Stefano Ugel; Elisa Tinazzi; Antonio Vella; Francesco De Sanctis; Stefania Canè; Veronica Batani; Rosalinda Trovato; Alessandra Fiore; Varvara Petrova; Francesca Hofer; Roza Maria Barouni; Chiara Musiu; Simone Caligola; Laura Pinton; Lorena Torroni; Enrico Polati; Katia Donadello; Simonetta Friso; Francesca Pizzolo; Manuela Iezzi; Federica Facciotti; Pier Giuseppe Pelicci; Daniela Righetti; Paolo Bazzoni; Marielisa Rampudda; Andrea Comel; Walter Mosaner; Caludio Lunardi; Oliviero Olivieri

    doi:10.1101/2020.06.26.20135319 Date: 2020-06-29 Source: medRxiv

    Severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2) is the causative agent of the ongoing pandemic coronavirus disease MESHD 2019 (COVID-19). The majority of patients with COVID-19 have a good prognosis, but variable percentages in different countries develop pneumonia HP pneumonia MESHD associated with lymphocytopenia MESHD and severe inflammatory response due to uncontrolled release of cytokines. These immune mediators are transcriptionally regulated by JAK-STAT molecular pathways, which can be disabled by small molecules. Here, we provide evidences on the efficacy of baricitinib, a JAK1/JAK2 inhibitor, in correcting the immune abnormalities observed in patients hospitalized with COVID-19. Indeed, we demonstrate a significant reduction in serum SERO levels of interleukin (IL)-6, IL-1{beta} and tumor necrosis MESHD factor (TNF), a rapid recovery in circulating T and B cell frequencies and an increased antibody SERO production against SARS-CoV-2 spike protein in baricitinib-treated patients. Moreover, treated patients underwent a rapid reduction in oxygen flow need and progressive increase in the P/F. Our work provides the basis on developing effective treatments against COVID-19 pathogenesis using on-target therapy.

    The Endothelial Dysfunction and Pyroptosis Driving the SARS-CoV-2 Immune- Thrombosis MESHD

    Authors: Seigo Nagashima; Monalisa Castilho Mendes; Ana Paula Camargo Martins; Nicolas Henrique Borges; Thiago Mateus Godoy; Anna Flavia Miggiolaro Ribeiro; Felipe da Silva Deziderio; Lucia de Noronha; Cleber Machado-Souza

    doi:10.1101/2020.06.17.20133124 Date: 2020-06-19 Source: medRxiv

    Objective: Endothelial activation after viral infection could contribute to changes in the vascular glycocalyx associated with programmed inflammatory cell death called pyroptosis. Thus, our goal is to recognize endothelial activation and pyroptosis in lung and myocardial samples of Coronavirus disease MESHD (COVID-19) cases and compare to H1N1pdm09 and control cases. Approach and Results: Post-mortem lung (6 cases of COVID-19 group; 10 cases of H1N1 group and 11 cases of Control group) and myocardial samples (2 cases of COVID-19 and one control) were analyzed by conventional immunohistochemistry by using antibodies SERO to identify molecules involving with endothelial activation (CD163, Interleukin-6 (IL-6), Tumor Necrosis MESHD Factor alpha (TNF-alpha), Intercellular Adhesion Molecule 1 (ICAM-1)) and pyroptosis (Caspase-1). As a result, IL-6, TNF-alpha, ICAM-1, and Caspase-1 show higher tissue expression in the COVID-19 group compared to H1N1 and Control groups. Conclusion: Our results indicate that the vascular endothelium has been activated and the presence of pyroptosis and endothelial dysfunction in lung and myocardial samples. These conditions could lead to a systemic immune- thrombotic process MESHD that may impair the clinical staff's efforts to prevent fatal outcomes. One aim of the health professionals is to avoid COVID-19 systemic vascular injury MESHD and immune-thrombosis MESHD by blocking the endothelial dysfunction and its consequences.

    Systemic Inflammatory Cytokines Associate With SARS-COV-2 Viral Shedding Time in Covid-19 Inpatients

    Authors: Jing Shi; Chongsheng Cheng; Muqing Yu; Xiaochen Li; Ke Wang; Yu Tao; Ying Zhou; Min Zhou; Shuyun Xu; Lu Qin; Zhenyu Yang; Cong Zhang; Junqing Yue; Xiansheng Liu; Harald Renz; Min Xie

    doi:10.21203/rs.3.rs-31556/v1 Date: 2020-05-26 Source: ResearchSquare

    Background: Since December 2019, coronavirus disease MESHD 2019 (COVID-19), as an infectious disease MESHD with cytokine storm, has become an emerging global challenge. To assess the duration of SARS-COV-2 viral shedding and associated risk factors in COVID-19 patients.Methods: COVID-19 patients with interleukin (IL)-1b, soluble interleukin-2 receptor (sIL-2R), IL-6, IL-8, IL-10 and tumor necrosis MESHD factor (TNF)-α cytokines data consecutively admitted to Tongji Hospital from January 27, 2020 through February 5, 2020 were enrolled and been followed up until March 24, 2020. We utilized Kaplan-Meier method and Cox proportional hazards regression analysis to assess the duration of viral shedding and risk factors affecting virus clearance.Results: 246 inpatients with laboratory confirmed COVID-19 were enrolled. The median duration of viral shedding was 24 days, ranging from 6 to 63 days. Age TRANS, severity of COVID-19, albumin, lactate dehydrogenase (LDH), D-dimer, ferritin and sIL-2R were associated with duration of viral shedding. Administration of lopinavir-ritonavir, arbidol, oseltamivir and intravenous immunoglobulin did not shorten viral shedding time. Multivariate cox regression analysis revealed that sIL-2R, LDH and severity of COVID-19 were independent factors associated with duration of viral shedding. At stratified analysis, the viral shedding time was positively correlated with age TRANS, sIL-2R and LDH in non-corticosteroid subgroup, while negatively correlated with lymphocyte count in corticosteroid group. Conclusions: The present study demonstrated that elevated sIL-2R, increased LDH and severe status were related to prolongation of viral shedding in COVID-19 inpatients. Further research is urgent to investigate the mechanism of immune reaction involved in the virus clearance process and aim to the optimal antiviral therapy.

    Examining the effector mechanisms of Xuebijing Injection on COVID-19 based on network pharmacology.

    Authors: Wenjiang Zheng; Qian Yan; Yongshi Ni; Shaofeng Zhan; Liuliu Yang; Hongfa Zhuang; Xiaohong Liu; Yong Jiang

    doi:10.21203/rs.3.rs-26834/v2 Date: 2020-05-03 Source: ResearchSquare

    Objective: To examine the potential effector mechanisms of Xuebijing (XBJ) on coronavirus disease MESHD 2019 (COVID-19) based on network pharmacology.Methods: We searched Chinese and international papers to obtain the active ingredients of XBJ. Then, we compiled COVID-19 disease targets from the GeneCards gene database and via literature searches. Next, we used the SwissTargetPrediction database to predict XBJ’s effector targets and map them to the abovementioned COVID-19 disease targets in order to obtain potential therapeutic targets of XBJ. Cytoscape software version 3.7.0 was used to construct a “XBJ active-compound-potential-effector target” network and protein-protein interaction (PPI) network, and then to carry out network topology analysis of potential targets. We used the ClueGO and CluePedia plugins in Cytoscape to conduct gene ontology (GO) biological process (BP) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) signaling pathway enrichment analysis of XBJ’s effector targets. Results: We obtained 144 potential COVID-19 effector targets of XBJ. Fourteen of these targets—glyceraldehyde 3-phosphate dehydrogenase (GAPDH), albumin (ALB), tumor MESHD necrosis MESHD factor (TNF), epidermal growth factor receptor (EGFR), mitogen-activated protein kinase 1 (MAPK1), Caspase-3 (CASP3), signal transducer and activator of transcription 3 (STAT3), MAPK8, prostaglandin-endoperoxide synthase 2 (PTGS2), JUN, interleukin-2 (IL-2), estrogen receptor 1 (ESR1), and MAPK14—had degree values >40 and therefore could be considered key targets. They participated in extracellular signal–regulated kinase 1 and 2 (ERK1, ERK2) cascade, the T-cell receptor signaling pathway, activation of MAPK activity, cellular response to lipopolysaccharide, and other inflammation MESHD- and immune-related BPs. XBJ exerted its therapeutic effects through the renin–angiotensin system (RAS), nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB), MAPK, phosphatidylinositol-4, 5-bisphosphate 3-kinase (PI3K)–protein kinase B (Akt)–vascular endothelial growth factor (VEGF), toll-like receptor (TLR), TNF, and inflammatory-mediator regulation of transient receptor potential (TRP) signaling pathways to ultimately construct a “ingredient-target-pathway” effector network. Conclusion: The active ingredients of XBJ regulated different genes, acted on different pathways, and synergistically produced anti-inflammatory and immune-regulatory effects, which fully demonstrated the synergistic effects of different components on multiple targets and pathways. Our study demonstrated that existing studies on the pharmacological mechanisms of XBJ in the treatment of sepsis HP sepsis MESHD and severe pneumonia HP pneumonia MESHD, could explain the effector mechanism of XBJ in COVID-19 treatment, and those provided a preliminary examination of the potential effector mechanism in this disease.

    Examining the effector mechanisms of Xuebijing Injection on COVID-19 based on network pharmacology

    Authors: Wenjiang Zheng; Qian Yan; Yongshi Ni; Shaofeng Zhan; Liuliu Yang; Hongfa Zhuang; Xiaohong Liu; Yong Jiang

    doi:10.21203/rs.3.rs-26834/v3 Date: 2020-05-03 Source: ResearchSquare

    Background: Chinese medicine Xuebijing (XBJ) has proven to be effective in the treatment of mild coronavirus disease MESHD 2019 (COVID-19) cases. But the bioactive compounds and potential mechanisms of XBJ for COVID-19 prevention and treatment are unclear. This study aimed to examine the potential effector mechanisms of XBJ onCOVID-19 based on network pharmacology.Methods: We searched Chinese and international papers to obtain the active ingredients of XBJ. Then, we compiled COVID-19 disease targets from the GeneCards gene database and via literature searches. Next, we used the SwissTargetPrediction database to predict XBJ’s effector targets and map them to the abovementioned COVID-19 disease targets in order to obtain potential therapeutic targets of XBJ. Cytoscape software version 3.7.0 was used to construct a “XBJ active-compound-potential-effector target” network and protein-protein interaction (PPI) network, and then to carry out network topology analysis of potential targets. We used the ClueGO and CluePedia plugins in Cytoscape to conduct gene ontology (GO) biological process (BP) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) signaling pathway enrichment analysis of XBJ’s effector targets. We used AutoDock vina and PyMOL software for molecular docking. Results: We obtained 144 potential COVID-19 effector targets of XBJ. Fourteen of these targets-glyceraldehyde 3-phosphate dehydrogenase (GAPDH), albumin (ALB), tumor MESHD necrosis MESHD factor (TNF), epidermal growth factor receptor (EGFR), mitogen-activated protein kinase 1 (MAPK1), Caspase-3 (CASP3), signal transducer and activator of transcription 3 (STAT3), MAPK8, prostaglandin-endoperoxide synthase 2 (PTGS2), JUN, interleukin-2 (IL-2), estrogen receptor 1 (ESR1), and MAPK14 had degree values >40 and therefore could be considered key targets. They participated in extracellular signal–regulated kinase 1 and 2 (ERK1, ERK2) cascade, the T-cell receptor signaling pathway, activation of MAPK activity, cellular response to lipopolysaccharide, and other inflammation MESHD- and immune-related BPs. XBJ exerted its therapeutic effects through the renin-angiotensin system (RAS), nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB), MAPK, phosphatidylinositol-4, 5-bisphosphate 3-kinase (PI3K)-protein kinase B (Akt)-vascular endothelial growth factor (VEGF), toll-like receptor (TLR), TNF, and inflammatory-mediator regulation of transient receptor potential (TRP) signaling pathways to ultimately construct a “drug-ingredient-target-pathway” effector network. The molecular docking results showed that the core 18 effective ingredients had a docking score of less than -4.0 with those top 10 targets. Conclusion: The active ingredients of XBJ regulated different genes, acted on different pathways, and synergistically produced anti-inflammatory and immune-regulatory effects, which fully demonstrated the synergistic effects of different components on multiple targets and pathways. Our study demonstrated that key ingredients and their targets have potential binding activity, the existing studies on the pharmacological mechanisms of XBJ in the treatment of sepsis HP sepsis MESHD and severe pneumonia HP pneumonia MESHD, could explain the effector mechanism of XBJ in COVID-19 treatment, and those provided a preliminary examination of the potential effector mechanism in this disease.

    The Aggressive Surgical Treatment and Outcome of a Colon Cancer HP Colon Cancer MESHD Patient Infected with SARS-CoV-2 in Wuhan, China and Our Experience Sharing

    Authors: Jinbo Gao; Ming Yang; Lian Liu; Shuang Guo; Yongfeng Li; Chao Cheng

    doi:10.21203/rs.3.rs-23214/v1 Date: 2020-04-16 Source: ResearchSquare

    Background:  Cancer MESHD patients are at increased risks of novelcoronavirus disease 2019 (COVID-19). Currently, surgical strategies for cancer MESHD patients with COVID-19 are generally suggested to be properly delayed. Case presentation:We presented a 69-year-old Chinese female  colon cancer MESHD patientwith COVID-19, the first case accepted the surgical treatment during the epidemic season in China. Thepatient developed a fever HP fever MESHD on January 28, 2020. After treatments with Ceftriaxone and Abidol, her fever HP fever MESHD was not reduced yet. A repeat chest computed tomography (CT) scan showed the infectious lesions significantly exacerbated, with a positive result for severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2) nucleic acid. An abdomen CT scan indicated the tumor MESHD of ascending colon with local wrapped changes. She was diagnosed with ‘Severe novel coronavirus pneumonia MESHD’ and ‘Incomplete bowel obstruction: Colon cancer HP Colon cancer MESHD?’. After actively anti-inflammatory and anti-viral therapies, aright colectomy with lymph node dissection was performed on March 11. The pathological changes of tissue specimens were further investigated.The patient successfully recovered from COVID-19 and surgery, without any postoperative related complications, and was discharged on the 9th day after operation. No case of surgeon, nurse or anesthetist in our team infected by SARS-CoV-2 occurred. Microscopically, significant degeneration MESHD, necrosis MESHD and slough of focal intestinal and colonic mucosal epithelial MESHD cells were observed. Conclusions:It is meaningful and imperative to share our experience to protect health care personnel from  SARS-CoV-2infection MESHD and to provide references for optimizing treatment of cancer MESHD patient, at least for the operative intervention absolutely necessary or emergency surgery,during the outbreak of COVID-19.

    Management of rheumatic diseases MESHD in the times of COVID-19 pandemic- perspectives of rheumatology practitioners from India

    Authors: Latika Gupta; Durga Misra; Vishwesh Agarwal; Suma Balan; Vikas Agarwal

    doi:10.1101/2020.04.03.20048389 Date: 2020-04-07 Source: medRxiv

    Background. The Coronavirus disease MESHD 19 (COVID-19) pandemic has led to widespread concerns about the risk of infection TRANS risk of infection TRANS infection MESHD in patients with rheumatic diseases MESHD ( RD MESHD) receiving disease modifying ant-rheumatic drugs (DMARDs) and other immunosuppressants (IS). Methods. A SurveyMonkey based electronic survey was conducted amongst members of the Indian Rheumatology Association to understand the need for changes in prevailing practices. Results. Of the 861 invitees, 221 responded. In the wake of the pandemic, 47.5% would reduce biological DMARDs (bDMARDs) while only 12.2% would reduce the use of conventional synthetic DMARDs. 64.2% were likely to defer change in IS, the reluctance being most with rituximab (58.3%) followed by cyclophosphamide (53.3%), anti- tumor MESHD necrosis MESHD factor alpha agents (52.4%) and Janus kinase inhibitors (34.39%). Hydroxychloroquine was the preferred choice (81.9%) for the treatment of COVID-19 followed by protease inhibitors (22.1%) and intravenous immunoglobulin (8.1%). Chloroquine was less preferred (19%). More than two-thirds (70.5%) believed that COVID-19 might trigger macrophage activation syndrome MESHD. Social distancing (98.1%) and hand hygiene (74.6%) were recommended by majority. 62.8% would avoid touch for clinical examination whenever feasible. Conclusion. Most rheumatologists perceived the need to change treatment of RDs during the COVID-19 pandemic; reduce immunosuppression and defer the usage of rituximab and bDMARDs.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.